CITIUS ONCOLOGY, INC.
Biopharmaceutical company developing and commercializing targeted oncology therapies.
CTOR | US
Overview
Corporate Details
- ISIN(s):
- US17331Y1091
- LEI:
- Country:
- United States of America
- Address:
- 11 COMMERCE DRIVE, 7016 CRANFORD
- Website:
- https://citiusonc.com/
- Sector:
- Manufacturing
Description
Citius Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative targeted oncology therapies. Its lead product, LYMPHIR™ (denileukin diftitox-cxdl), is a targeted immune therapy approved by the U.S. Food and Drug Administration (FDA) in August 2024. LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company's strategy involves expediting development pathways for treatments with reduced clinical risks and securing competitive advantages through intellectual property and regulatory exclusivity. Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, Inc.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CITIUS ONCOLOGY, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CITIUS ONCOLOGY, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CITIUS ONCOLOGY, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
